Grifols (GIFLF) Payables (2009 - 2025)
Grifols' (GIFLF) quarterly Payables came in at $1.3 billion in Q4 2025, up 8.45% on a YoY basis from $1.2 billion in Q4 2024, and up 8.45% quarter-over-quarter from $1.2 billion in Q4 2024.
Analysis
Grifols (GIFLF) Payables (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Payables for 17 consecutive years, with $1.3 billion the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Payables rose 8.45% year-over-year to $1.3 billion; the trailing twelve-month figure through Dec 2025 stood at $1.3 billion (up 8.45% YoY), and the FY2025 full-year result was $1.3 billion, up 5.26% from the prior year.
- Payables climbed to $1.3 billion in Q4 2025 per GIFLF's latest filing, from $1.2 billion in the prior quarter.
- Across five years, Payables topped out at $1.3 billion in Q4 2025 and bottomed at $898.4 million in Q4 2021.
- Historically, Payables has averaged $1.1 billion across 5 years, with a median of $1.0 billion in 2023.
- The sharpest annual moves came in 2021 and 2024: Payables increased 0.98% in 2021, then advanced 14.91% in 2024.
- Over 5 years, Payables stood at $898.4 million in 2021, then rose by 4.32% to $937.2 million in 2022, then advanced by 11.44% to $1.0 billion in 2023, then rose by 14.91% to $1.2 billion in 2024, then climbed by 8.45% to $1.3 billion in 2025.
- According to Business Quant data, Payables over the past three periods registered $1.3 billion, $1.2 billion, and $1.0 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 2.87 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 674.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 429.50 Mn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 1.16 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 167.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 403.90 Mn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 25.08 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 1.30 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 1.30 Bn |
| Dec 31, 2024 | 1.20 Bn |
| Dec 31, 2023 | 1.04 Bn |
| Dec 31, 2022 | 937.18 Mn |
| Dec 31, 2021 | 898.41 Mn |
| Dec 31, 2020 | 889.67 Mn |
| Dec 31, 2019 | 834.02 Mn |
| Dec 31, 2018 | 825.93 Mn |
| Jun 30, 2018 | 705.10 Mn |
| Dec 31, 2017 | 672.93 Mn |
| Jun 30, 2017 | 599.76 Mn |
| Dec 31, 2016 | 660.71 Mn |
| Sep 30, 2016 | 554.06 Mn |
| Jun 30, 2016 | 601.04 Mn |
| Dec 31, 2015 | 583.52 Mn |
| Sep 30, 2015 | 521.18 Mn |
| Jun 30, 2015 | 616,137.26 |
| Mar 31, 2015 | 635.73 Mn |
| Dec 31, 2014 | 772.47 Mn |
| Sep 30, 2014 | 660.83 Mn |